Skip to content
value.today

Intarcia Therapeutics, Inc.

Total raised
$1.0 B
8 rounds on record
Latest round
$199 M
Feb 2019
First round on record
Nov 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Intarcia Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2019$199 MNo. 8$50 to $250 million

Intarcia Therapeutics, Inc.: Raise no. 8, Feb 2019

Investors in this round

45 investors had bought by the notice of Jan 14, 2020: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$199 M of $280 M offered; $82 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anders Vinther · Executive Officer
  • David Spellman · Executive Officer
  • Fred Fiedorek · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Paul Feldman · Executive Officer
  • Raymond Keane · Executive Officer
  • Thane Wettig · Executive Officer
  • Bob Kerrey · Director
  • Bryan Roberts · Director
  • Gino Santini · Director
  • Jay Skyler · Director
  • Jim Rosenthal · Director
  • Nancy Thornberry · Director
  • Patrick Conway · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Morgan Stanley & Co. LLC (CRD 8209) · New York, New YorkSold in CA, MA, NC, NJ, PA, SD

Signed by Kurt Graves, Chief Executive Officer. Newest notice filed Jan 14, 2020. Read the notice at the SEC.

debt, optionsSEC
Sep 2016$525 MNo. 7$250 million to $1 billion

Intarcia Therapeutics, Inc.: Raise no. 7, Sep 2016

Investors in this round

90 investors had bought by the notice of Aug 4, 2017: 90 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$525 M of $850 M offered; $325 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$15,908,222
Finders' fees
$218,015
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony Hurley · Executive Officer
  • James Ahlers · Executive Officer
  • Jay Smith · Executive Officer
  • John Yee · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Michelle Baron · Executive Officer
  • Owen Hughes, Jr. · Executive Officer
  • Paul Feldman · Executive Officer
  • Raymond Keane · Executive Officer
  • Sunita Zalani · Executive Officer
  • Thomas Alessi · Executive Officer
  • Bryan Roberts · Director
  • Emad Rizk · Director
  • Gino Santini · Director
  • Glen Sato · Director
  • Irwin Scher · Director
  • Nancy Thornberry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Raptor International, LLC · Abu Dhabi, United Arab EmiratesSold in no state named, and outside the US
  • UBS Securities LLC (CRD 7654) · City State/Province/Country Zi, New YorkSold in AL, AR, AZ, CA, CO, CT, FL, GA, IL, IN, LA, MA, MI, MN, MT, NC, NE, NH, NJ, NV, NY, OK, PA, SC, TN, TX, VA, WA, WY, and outside the US
  • Brooklands Capital Strategies BD, LP · Fort Worth, TexasSold in all US states, and outside the US
  • OUISA CAPITAL, LLC · New York, New YorkSold in all US states
  • Morgan Stanley & Co. LLC (CRD 8209) · New York, New YorkSold in AL, AR, AZ, CA, CO, CT, DC, FL, GA, IA, IL, KS, LA, MA, MD, MI, MO, MS, NC, NJ, NV, NY, OH, OK, PA, RI, SC, TN, TX, VA, WA, and outside the US

Signed by Raymond T. Keane, Vice President, General Counsel and Chief Legal Officer. Newest notice filed Aug 4, 2017 (3 amendments). Read the notice at the SEC.

equitySEC
Mar 2014$200 MNo. 6$50 to $250 million

Intarcia Therapeutics, Inc.: Raise no. 6, Mar 2014

Investors in this round

38 investors had bought by the notice of Apr 7, 2014: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
$14,446
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Franklin · Executive Officer
  • James Ahlers · Executive Officer
  • Jay T. Smith · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Michelle Baron · Executive Officer
  • Owen Hughes, Jr. · Executive Officer
  • Raymond T. Keane · Executive Officer
  • Thomas Alessi · Executive Officer
  • Bryan T. Roberts · Director
  • Gino Santini · Director
  • Glen Sato · Director
  • Irwin Scher · Director
  • Nancy Thornberry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Raymond T. Keane, Vice President, General Counsel and Chief Legal Officer. Newest notice filed Apr 7, 2014. Read the notice at the SEC.

equitySEC
Nov 2012$8 MNo. 5$2 to $10 million

Intarcia Therapeutics, Inc.: Raise no. 5, Nov 2012

Investors in this round

15 investors had bought by the notice of Nov 29, 2012: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara McClung · Executive Officer
  • David Franklin · Executive Officer
  • James Ahlers · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Michelle Baron · Executive Officer
  • Thomas Alessi · Executive Officer
  • Ed Mathers · Director
  • Glen Sato · Director
  • Irwin Scher · Director
  • James Niedel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Repayment of debt.”

Signed by Barbara McClung, Secretary. Newest notice filed Nov 29, 2012 (1 amendment). Read the notice at the SEC.

equitySEC
Aug 2012$7 MNo. 4$2 to $10 million

Intarcia Therapeutics, Inc.: Raise no. 4, Aug 2012

Investors in this round

1 investor had bought by the notice of Aug 22, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara J. McClung · Executive Officer
  • David J. Franklin · Executive Officer
  • James Ahlers · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Michelle J. Baron · Executive Officer
  • Thomas J. Alessi · Executive Officer
  • Bryan J. Roberts · Director
  • Ed J. Mathers · Director
  • Glen J. Sato · Director
  • Irwin J. Scher · Director
  • James J. Niedel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Working capital and general corporate purposes.”

Signed by Barbara McClung, Secretary. Newest notice filed Aug 22, 2012. Read the notice at the SEC.

debt, optionsSEC
Aug 2010$46 MNo. 3$10 to $50 million

Intarcia Therapeutics, Inc.: Raise no. 3, Aug 2010

Investors in this round

35 investors had bought by the notice of Aug 30, 2012: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$46 M of $48 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara J. McClung · Executive Officer
  • David J. Franklin · Executive Officer
  • James Ahlers · Executive Officer
  • Kurt Graves · Executive Officer, Director
  • Michelle J. Baron · Executive Officer
  • Thomas J. Alessi · Executive Officer
  • Bryan J. Roberts · Director
  • Ed J. Mathers · Director
  • Glen J. Sato · Director
  • Irwin J. Scher · Director
  • James J. Niedel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Working capital and general corporate purposes.”

Signed by Barbara McClung, Secretary. Newest notice filed Aug 30, 2012 (3 amendments). Read the notice at the SEC.

debt, optionsSEC
Mar 2010$14 MNo. 2$10 to $50 million

Intarcia Therapeutics, Inc.: Raise no. 2, Mar 2010

Investors in this round

30 investors had bought by the notice of May 14, 2010: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $16 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara G. McClung · Executive Officer
  • David J. Franklin · Executive Officer
  • James M. Ahlers · Executive Officer
  • K. Alice Leung · Executive Officer, Director
  • Kenneth L. Luskey · Executive Officer
  • Thomas R. Alessi · Executive Officer
  • Bryan R. Roberts · Director
  • Ed R. Mathers · Director
  • Glen R. Sato · Director
  • Irwin R. Scher · Director
  • James R. Niedel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes loan amount and warrant purchase price. It does not include the exercise price of the shares.”
  • On the use of proceeds: “Proceeds will be used for working capital.”

Signed by Barbara G. McClung, V.P., General Counsel, Secretary. Newest notice filed May 14, 2010. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2009$9 MNo. 1$2 to $10 million

Intarcia Therapeutics, Inc.: Raise no. 1, Nov 2009

Investors in this round

33 investors had bought by the notice of Jan 15, 2010: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara G. McClung · Executive Officer
  • David J. Franklin · Executive Officer
  • James M. Ahlers · Executive Officer
  • K. Alice Leung · Executive Officer, Director
  • Kenneth L. Luskey · Executive Officer
  • Thomas R. Alessi · Executive Officer
  • Bryan R. Roberts · Director
  • Ed R. Mathers · Director
  • Glen R. Sato · Director
  • Irwin R. Scher · Director
  • James R. Niedel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes loan amount, price of Series BB shares sold and warrant purchase price. It does not include the exercise price of the shares.”
  • On the use of proceeds: “Proceeds will be used for working capital.”

Signed by Barbara G. McClung, V.P., General Counsel, Secretary. Newest notice filed Jan 15, 2010 (1 amendment). Read the notice at the SEC.

equity, debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Intarcia Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2020).

    SEC Form D · Jan 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2020

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

No investor of Intarcia Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Intarcia Therapeutics, Inc.
NameRoleNamed in
Anders VintherExecutive officerJan 2020
David SpellmanExecutive officerJan 2020
Fred FiedorekExecutive officerJan 2020
Kurt GravesExecutive officerJan 2020
Paul FeldmanExecutive officerJan 2020
Raymond KeaneExecutive officerJan 2020
Thane WettigExecutive officerJan 2020
Anthony HurleyExecutive officerAug 2017
James AhlersExecutive officerAug 2017
Jay SmithExecutive officerAug 2017
John YeeExecutive officerAug 2017
Michelle BaronExecutive officerAug 2017
Owen Hughes, Jr.Executive officerAug 2017
Sunita ZalaniExecutive officerAug 2017
Thomas AlessiExecutive officerAug 2017
Michael WilliamsExecutive officerSep 2016
David FranklinExecutive officerApr 2014
Jay T. SmithExecutive officerApr 2014
Raymond T. KeaneExecutive officerApr 2014
Barbara McClungExecutive officerNov 2012
Barbara J. McClungExecutive officerAug 2012
David J. FranklinExecutive officerAug 2012
Michelle J. BaronExecutive officerAug 2012
Thomas J. AlessiExecutive officerAug 2012
Barbara L. McClungExecutive officerAug 2011
James Alice AhlersExecutive officerAug 2011
K. Alice LeungExecutive officerAug 2011
Kenneth L. LuskeyExecutive officerAug 2011
Thomas L. AlessiExecutive officerAug 2011
Barbara G. McClungExecutive officerMay 2010
James M. AhlersExecutive officerMay 2010
Thomas R. AlessiExecutive officerMay 2010
David D. FranklinExecutive officerDec 2009
James D. AhlersExecutive officerDec 2009
Kenneth D. LuskeyExecutive officerDec 2009
Tom G. AlessiExecutive officerDec 2009
Bob KerreyDirectorJan 2020
Bryan RobertsDirectorJan 2020
Gino SantiniDirectorJan 2020
Jay SkylerDirectorJan 2020

About

American pharmaceutical company.